A review.In this issue of Blood, Yu et al identify the role of enterocyte RIPK1/RIPK3 in the generation of graft-vs.-host disease (GVHD) and generate a potent RIPK1 inhibitor, Zharp1-211, which inhibits GVHD without impacting graftversus-leukemia (GVL) in a murine model.